Metrics Contract Services, a full-service contract pharmaceutical formulation development and manufacturing organization, has adopted a new and more descriptive name.
Packaging Coordinators has reached a definitive agreement to acquire Penn Pharmaceutical...
Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that...
Aptuit Names Executive VP, Business Development & Marketing; Enhances Sterile Drug Product CapabilitiesJuly 16, 2014 11:33 am | News | Comments
Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business...
Chiltern and Ockham, two full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services.
AAIPharma Services Corp., a global provider of pharmaceutical analytical testing, product development and manufacturing services, and Cambridge Major Laboratories, Inc., a provider pharmaceutical API development and manufacturingservices, announced the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014.
Metrics Inc. has expanded its already robust options for enhancing drug bioavailability thanks to the recent acquisition of a BÜCHI B-290 Mini Spray Dryer. The dryer’s core capability is rendering powder from a solution, said Brad Gold, Ph.D., vice president of pharmaceutical development.
Bioanalytical Systems, Inc. (BASi) today announced the appointment of Jeffrey Potrzebowski as Chief Financial Officer and James S. Bourdage, Ph.D., as Vice President Bioanalytical Operations.
Xcelience announced today the opening of a 3,000 square foot facility in Birmingham, UK, making it the first small to mid-sized American CDMO to launch international operations. The new plant will become a gateway for the Florida-based company’s clinical packaging and distribution services in the UK, Europe and abroad.
AMRI has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, for $110M in cash. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations.
Hikma will be acquiring Bedford Laboratories' assets, including a large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong research and development and business development pipeline, and a number of employees across key business functions.
WuXi PharmaTech today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services.
Albany Molecular Research Inc. announced Wednesday that it will close its 12-year-old facility in Cicero on July 15. Some employees will be transferred to Albany, Cedarburg, Wis., England and India.
OsoBio has appointed Catherine R. Buck director of manufacturing. In her capacity, Buck is responsible for ensuring that OsoBio’s operations comply with current Good Manufacturing Practices (cGMP) as they apply to the manufacturing of injectable sterile liquid, suspension and lyophilized pharmaceutical products.
Quintiles has announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr. Blackburn will be responsible for leading the group’s risk management efforts in North America, EU and Asia-Pacific.
AMRI has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million.
With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China.
Almac has announced the expansion of its clinical services and technologies capabilities to include on-the-ground leadership as well as technical, project and operational resources in Asia. The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from the region.
Progenitor Cell Therapy has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice facilities to significantly increase its engineering and process development laboratories, and controlled environment space available for client needs.
Olympus Biotech today announced the initiation of an aggressive transaction process to find a buyer of its West Lebanon, NH manufacturing facility over the next 90 days. In recent months, the Company has received interest from buyers and contract manufacturing organization (CMO) partners, but no deal has been consummated yet.
Andrew Sandford joins Catalent as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings and, Dr. Jennifer Mitcham jas been appointed Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics.
Pharmaceutical Product Development, LLC (PPD) has appointed Patrick Bennett as executive director of laboratory operations for a new biomarker services division of its bioanalytical laboratory.
OsoBio has appointed Paul W. Stoker, Ph.D., director of its chemistry and microbiology laboratories. Stoker fills a position vacated when Kathleen Larese, OsoBio’s previous director of laboratories, became the company’s director of technical operations.
Pharmaceutical Processing's Editor In Chief Mike Auerbach discusses current and future outsourcing trends with a select group of companies.
Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations in the United States, and for spearheading new business development initiatives.
Unique Pharmaceuticals, Ltd. has voluntarily registered with the U.S. Food and Drug Administration (FDA) as a Human Drug Compounding Outsourcing Facility following guidance from the recently enacted Drug Quality and Security Act.
CCBR-SYNARC and BioClinica, Inc. have signed an agreement to merge their companies to create a global provider of specialized outsourced clinical services. The combined company will offer a portfolio of services uniquely tailored to conducting and managing global clinical trials on behalf of the world's premier pharmaceutical and biotechnology companies.
AAIPharma Services a provider of pharmaceutical analytical testing, product development and manufacturing services, announced today that it has completed a multi-million dollar expansion of its cGMP parenteral manufacturing facility in Charleston, S.C.
- Page 1